Aclaris Therapeutics, Inc (ACRS)

Etorro trading 970x250

About Aclaris Therapeutics, Inc

Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 640 Lee Road, Wayne, PA, United States, 19087

Aclaris Therapeutics, Inc News and around…

Latest news about Aclaris Therapeutics, Inc (ACRS) common stock and company :

Looking Into Aclaris Therapeutics Return On Capital Employed
09 Aug, 2022 FinancialContent

Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q2 sales of $1.53 million. The company posted a loss of $20.53 ...

Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt?
05 Aug, 2022 Yahoo! Finance

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Aclaris Therapeutics: Q2 Earnings Insights
03 Aug, 2022 FinancialContent

Aclaris Therapeutics (NASDAQ:ACRS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's ...

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
03 Aug, 2022 Yahoo! Finance

Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
03 Aug, 2022 Yahoo! Finance

•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update. “It has been a busy first half of the year as we continue in ou

ACRS Makes Notable Cross Below Critical Moving Average
01 Aug, 2022 FinancialContent

In trading on Monday, shares of Aclaris Therapeutics Inc (ACRS) crossed below their 200 day moving average of $14.27, changing hands as low as $14.16 per share. Aclaris Therapeutics Inc shares are currently trading off about 6.7% on the day..

Aclaris Therapeutics Expands Leadership Team
01 Aug, 2022 Yahoo! Finance

Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as President and Chief Operating Officer. Dr. Manion will be responsible for overseeing day-to-day operations, continuing to develop Aclaris’ infrastructure and

Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy
15 Jul, 2022 Yahoo! Finance

Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
08 Jul, 2022 Yahoo! Finance

Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options
01 Jul, 2022 Yahoo! Finance

This week's Lab Notes has items on a Chester County company's ongoing pursuit of approval for its lead drug candidate, a Bucks County company exploring its options after generating positive study results for an experimental angina drug, two local life sciences companies naming new chief medical officers, and more.

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
22 Jun, 2022 Yahoo! Finance

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Analysts See 52% Gains Ahead For XPH
21 Jun, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $59.65 per unit.

Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
20 Jun, 2022 Yahoo! Finance

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect?
13 Jun, 2022 Yahoo! Finance

The consensus price target hints at a 141% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Aclaris Therapeutics's Return On Capital Employed Insights
08 Jun, 2022 FinancialContent

According to data from Benzinga Pro, during Q1, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.45 million. Despite a ...

Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?
06 Jun, 2022 Yahoo! Finance

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
01 Jun, 2022 Yahoo! Finance

WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York. Management will be available June 8th for 1x1 meetings. A live webcast of the fi

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade
27 May, 2022 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 179.1% in Aclaris (ACRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
17 May, 2022 Yahoo! Finance

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

Look Under The Hood: ESML Has 40% Upside
17 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.57 per unit.

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
16 May, 2022 Yahoo! Finance

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. Management will be available May 23rd throughout the

Recap: Aclaris Therapeutics Q1 Earnings
10 May, 2022 FinancialContent

Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what ...

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
10 May, 2022 Yahoo! Finance

Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
10 May, 2022 Yahoo! Finance

Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update. “We have continued to progress our clinical programs, including activating

Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates
04 May, 2022 Yahoo! Finance

Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
03 May, 2022 Yahoo! Finance

WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on Wednesday, May 11, 2022 at 9:00 a.m. ET. A webcast

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
02 May, 2022 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Airbnb And 3 Other Stocks Insiders Are Selling
26 Apr, 2022 FinancialContent

Although gold futures traded higher this morning on Tuesday, there were a few notable insider trades. When insiders sell shares, it ...

Analysts Anticipate 41% Gains Ahead For XPH
11 Apr, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $65.19 per unit.

Analysts Predict 58% Gains Ahead For XPH
23 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $67.18 per unit.

Aclaris Therapeutics, Inc (ACRS) is a NASDAQ Common Stock listed in , ,

970x250